Join us as we strive to make the unprecedented possible.

At Centessa, we embrace our core values in order to discover and develop truly transformational medicines for patients. We are pragmatic, make hard decisions daily, work with a sense of urgency and expect extraordinary results. We challenge the status quo and share a passion for science. We are a global medical research team and together, we are a transformational pharmaceutical company.

Our Core Values

Innovation
Innovation
careers-icon-values-integrity
Integrity
careers-icon-values-collaboration
Collaboration
careers-icon-values-agility
Accountability
Explore Our Opportunities

 

Fraud Job Warning

 Please note that fraudsters and cyber criminals have been using fake accounts via LinkedIn and other sources to falsely advertise medical research jobs available at Centessa Pharmaceuticals. We have been informed of the use of the following emails in particular: hengyuan@centessascareers and hr@centessascareers. These are not legitimate Centessa jobs or emails and no person using these emails represent Centessa. Any roles advertised by Centessa are advertised on our website. If you do not see an advertisement on our website, it is a fake and should be reported. You can find guidance on legitimate government websites such as the FBI website on how to identify fake jobs and to protect yourself against job scams.

For further information on how Centessa processes your personal data in relation to recruitment activities, read our Candidate Privacy Notice.
READ
Scroll to Top
pipeline chart header registrational white
SerpinPC

Overview
SerpinPC is a subcutaneously administered novel inhibitor of APC being developed as a potential treatment for hemophilia, regardless of severity or inhibitor status, and may also prevent bleeding associated with other bleeding disorders. Centessa is advancing the registrational program for SerpinPC in hemophilia B, which includes a set of clinical studies with multiple components. PRESent-5, initiated in late 2022, is an observational feeder study to collect prospective observational data for minimum defined periods before switching to dosing subjects in the interventional studies. The interventional studies include PRESent-2 (moderately severe to severe hemophilia B without inhibitors, and severe hemophilia A with and without inhibitors) and PRESent-3 (hemophilia B with inhibitors). Additional information on the trials can be accessed at www.clinicaltrials.gov  (NCT05605678, NCT05789524, NCT05789537). SerpinPC is an investigational agent that has not been approved by the FDA or any other regulatory authority.

Reason to Believe in Target
Human Genetics Support

Epidemiology
~20,000 persons with hemophilia in the United States
450,000 estimated global prevalence
Disease

Hemophilia B